Hester Biosciences Limited — Updates, 12-11-2025: General Updates
12-11-2025 | 03:36 pm
12-11-2025 | 03:36 pm
HesterBio's H1 FY26 saw India sales drop (Q2: 64 Cr, down 12%) due to delayed government animal health programs. Consolidated net profit jumped 99% (FX effect). Poultry segment grew 18%, and the H9N2 vaccine was approved. 182 Cr plant capex will boost future growth.
No comments yet. Be the first to comment!
